[Status and trends in the field of inhibitors of thrombocyte function].
The pharmacological control of platelet functions was discussed. Besides specific receptor antagonists of aggregatory agents, drugs inhibiting the arachidonate metabolism and thus formation of thromboxane A2 proved to be inhibitors of platelet aggregation. Drugs influencing the cAMP level of platelets via activation of adenylate cyclase or inhibition of phosphodiesterase have a broad spectrum of inhibitory effects. By the combined use of inhibitors of platelet function potentiation of their effects is expected.
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects*; D000242:Cyclic AMP / Q000097:blood; D016861:Cyclooxygenase Inhibitors; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D013876:Thiophenes / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D013988:Ticlopidine
D016861:Cyclooxygenase Inhibitors; D013876:Thiophenes; D000242:Cyclic AMP; D013930:Thromboxane-A Synthase; D013988:Ticlopidine
Stand und Entwicklungstendenzen auf dem Gebiet der Thrombozytenfunktionshemmstoffe.